Changing the natural history of HIV disease

Lancet

Volumn 348, Issue 9022, 1996, Pages 239-246

  Feinberg, Mark B ^a  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT;

DISEASE COURSE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; PRIORITY JOURNAL; REVIEW; VIRUS PATHOGENESIS; VIRUS REPLICATION;

EID: 0030603841     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(96)06231-9     Document Type: Review

References (48)

1. 1 Gullick RM, Mellors J, Havlir D, et al. Potent and sustained antiretroviral activity of indinavir, zidovudine, and lamivudine. XI International Conference on AIDS, Vancouver, BC, July 7-12, 1996 (abstr Th.B.931): 19.
2. 2 Coffin JM. HIV population dynamics in vivo: implications for genetic variation, pathogenesis, and therapy. Science 1995; 267: 483-89.
3. 3 Ho DD, Neumann AU, Perelson AS, Chen W, Leonard JM, Markowitz M. Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection. Nature 1995; 373: 123-26.
4. 4 Perelson AS, Neumann AU, Markowitz M, Leonard JM, Ho DD. HIV-1 dynamics in vivo: virion clearance rate, infected cell life-span, and viral generation time. Science 1996; 271: 1582-86.
5. 5 Wei X, Ghosh SK, Taylor ME, et al. Viral dynamics in human immunodeficiency virus type 1 infection. Nature 1995; 373: 117-22.
6. 6 Kitahata MM, Koepsell TD, Deyo RA, Maxwell CL, Dodge WT, Wagner EH. Physicians' experience with the acquired immunodeficiency syndrome as a factor in patients' survival. N Engl J Med 1996; 334: 701-06.
7. 7 Feinberg MB. Human retrovirus infections. In: Scientific American Medicine, 1995; 7; XXXIIB: 1-38. New York: Scientific American, 1995.
8. 8 Weiss RA. HIV receptors and the pathogenesis of AIDS. Science 1996; 272: 1885-86.
9. 9 Enger C, Graham N, Peng Y, et al. Survival from early, intermediate, and late stages of HIV infection. JAMA 1996; 275: 1329-34.
10. 10 Kaplan JE, Masur H, Jaffe HW. Reducing the impact of opportunistic infections in patients with HIV infection. JAMA 1995; 274: 347-48.
11. 11 USPHS/IDSA Prevention of Opportunistic Infections Working Group. USPHS/IDSA guidelines for the prevention of opportunistic infections in persons infected with human immunodeficiency virus: a summary. Ann Intern Med 1996; 124: 348-61.
12. 12 Stein DS, Korvick JA, Vermund SH. CD4+ lymphocyte cell enumeration for prediction of clinical course of human immunodeficiency virus disease: a review. J Infect Dis 1992; 165: 352-63.
13. 13 Koot M, B van't Wout A, Kootstra NA, E Y de Goede R, Tersmette M, Schuitemaker H. Relation between changes in cellular load evaluation of viral phenotype, and the clonal composition of virus populations in the course of human immunodeficiency virus type infection. J Infect Dis 1996; 173: 349-54.
14. 14 Haynes BF, Panteleo G, Fauci AS. Toward an understanding of the correlates of protective immunity to HIV infection. Science 1996; 271: 324-28.
15. 15 Kirchoff F, Greenough TC, Brettler DB, Sullivan JL, Desrosiers RC. Brief report: absence of intact nef sequences in a long-term survivor with non-progressive HIV-1 infection. N Engl J Med 1995; 332: 228-32.
16. 16 Deacon NJ, Tsykin A, Solomon A, et al. Genomic structure of an attenuated quasi species of HIV-1 from a blood transfusion donor and recipients. Science 1995; 270: 988-91.
17. 17 Kaslow RA, Carrington M, Apple R, Park L, Munoz A, Saah AJ. Influence of combinations of human major histocompatibility complex genes on the course of HIV-1 infection. Nature Med 1996; 4: 405-11.
18. 18 Paxton WA, Martin SR, Tse D, O'Brien TR, Skurnick J, et al. Relative resistance to HIV-1 infection of CD4 lymphocytes from persons who remain uninfected despite multiple high-risk sexual exposures. Nature Med 1996; 4: 412-17.
19. 19 Darby SC, Weart DW, Giangrande PLF, et al. Importance of age at infection with HIV-1 for survival and development of AIDS in UK haemophilia population. Lancet 1996; 347: 1573-79.
20. 20 Staprans SI, Hamilton BL, Follansbee SE, et al. Activation of virus replication after vaccination of HIV-1-infected individual. J Exp Med 1995; 182: 1727-37.
21. 21 Stanley SK, Ostrowski MA, Justement JS, et al. Effect of immunization with a common recall antigen in viral expression in patients infected with human immunodeficiency virus type 1. N Engl J Med 1996; 334: 1222-30.
22. 22 Piatak M, Saag M, Yang L, et al. High levels of HIV-1 in plasma during all stages of infection determined by competitive PCR. Science 1993; 259: 1749-54.
23. 23 Saag MS, Holodniy M, Kuritzkes DR, et al. HIV viral load markers in clinical practice. Nature Med 1996; 2: 625-29.
24. 24 Pachl C, T odd J, Kern D, et al. Rapid and precise quantification of HIV-1 RNA in plasma using a branched DNA (bDNA) signal amplification assay. J AIDS 1995; 8: 446-54.
25. 25 Mulder J, McKinney N, Christopherson C, Sninsky J, Greenfield L, Kwok S. Rapid and simple PCR assay for quantitation of human immunodeficiency type 1 RNA in plasma: application to acute retroviral infection. J Clin Microbiol 1994; 32: 292-300.
26. 26 Vandamme AM, Van Dooren S, Kok W, et al. Detection of HIV-1 RNA in plasma and serum samples using the NASBA amplification system compared to RNA-PCR. J Virol Methods 1995; 52: 121-32.
27. 27 Cao Y, Ho D, Todd J, Kokka R, Urdea M, Lifson J, et al. Clinical evaluation of branched DNA signal amplification for quantifying HIV type 1 in human plasma. AIDS Res Hum Retrovir 1995; 11: 353-61.
28. 28 Henrard DR, Phillips JF, Muenz LR, et al. Natural history of HIV-1 cell-free viremia. JAMA 1995; 274: 554-58.
29. 29 Jurriaans S, van Gemen B, Weverling GJ, et al. The natural history of HIV-1 infection: virus load and virus phenotype independent determinants of clinical course? Virology 1994; 204: 223-33.
30. 30 Mellors JW, Kingsley LA, Rinaldo CR, Hoo BS, Kokka RP, Gupta P. Quantitation of HIV-1 RNA in plasma predicts outcome after seroconversion. Ann Intern Med 1995; 112: 573-79.
31. 31 Mellors JW, Rinaldo C, Gupta P, White RM, Todd JA, Kingsley LA. Prognosis in HIV-1 infection predicted by the quantity of virus in plasma. Science 1996; 272: 1167-70.
32. 32 Embretson J, Zupancic M, Ribas J, et al. Massive covert infection of helper T lymphocytes and macrophages by HIV during the incubation period of AIDS. Nature 1993; 362: 359-62.
33. 33 Saksela K, Stevens CE, Rubenstein P, Taylor PE, Baltimore D. HIV-1 messenger RNA in peripheral blood mononuclear cells with an early marker of risk for progression to AIDS. Ann Intern Med 1995; 123: 641-48.
34. 34 O'Brien WA, Hartigan PM, Martin D, et al. Changes in plasma HIV-1 RNA and CD4+ lymphocyte counts and the risk of progression to AIDS. N Engl J Med 1996; 334: 426-31.
35. 35 Coombs RW, et al. Assocation of plasma human immunodeficiency virus type-1 RNA level with risk of clinical progression in patients with advanced infection. J Infect Dis (in press).
36. 36 Wells SL, et al. Prognostic value of plasma HIV-1 RNA levels in patients with advanced disease with little or no zidovudine therapy. J Infect Dis (in press).
37. 37 Tindall B, Cooper DA. Primary HIV infection: host responses and intervention strategies. AIDS 1991; 5: 1-14.
38. 38 Kinlock-De Loes S, Hirschel B, Hoen B, et al. A controlled trial of zidovudine in primary human immunodeficiency virus infection. N Engl J Med 1995; 333: 408-13.
39. 39 Ho D. Time to hit HIV, early and hard. N Engl J Med 1995; 333: 450-51.
40. 40 Schnittman S, Lane HC, Greenhouse J, et al. Preferential infection of CD4+ memory T cells by human immunodeficiency virus type 1: evidence for a role in selective T-cell functional defects observed in infected individuals. Proc Natl Acad Sci USA 1990; 87: 6058-62.
41. 41 Shearer G, Clerici M. Early T-helper cell defects in HIV infection. AIDS 1991; 5: 245-53.
42. 42 Stein DS, Graham NMH, Park LP, et al. The effect of the interaction of acyclovir with zidovudine on progression to AIDS and survival. Ann Intern Med 1994; 121: 100-08.
43. 43 Pape JW, Jean SS, Ho JL, Hafner A, Johnson WD. Effect of isoniazid prophylaxis on incidence of active tuberculosis and progession of HIV infection. Lancet 1993; 342: 268-72.
44. 44 Whalen C, Horsburgh CR, Hom D, Lahart C, Simberkoff M, Ellner J. Accelerated course of human immunodeficiency virus infection after tuberculosis. Am J Respir Crit Care Med 1995; 151: 129-35.
45. 45 Pantaleo G, Graziosi C, Demarest J, et al. HIV infection is active and progressive in lymphoid tissue during the clinically latent stage of disease. Nature 1993; 362: 355-58.
46. 46 Mackall CL, Fleisher TA, Brown MR, et al. Age, thymopoiesis, and CD4+ T-lymphocyte regeneration after intensive chemotherapy. N Engl J Med 1995; 332: 143-49.
47. 47 Margolick JB, Munoz A, Donnenberg AD, et al. Failure of T-cell homeostasis preceding AIDS in HIV-1 infection. Nature Med 1995; 7: 674-80.
48. 48 Kovacs JA, Baseler M, Dewar RJ, et al. Increase in CD4 T lymphocytes with intermittent courses of interleukin-2 in patients with human immunodeficiency virus infection. N Engl J Med 1995; 332: 567-75.